RANI THERAPEUTICS HOLDINGS-A (RANI)

Company Profile

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 140 full-time employees. The company went IPO on 2021-07-30. The firm is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Company Info

RANI THERAPEUTICS HOLDINGS-A

2051 Ringwood Avenue

San Jose CALIFORNIA

P: 14084573700

CEO: Talat Imran

Employees: 140

Website: https://www.ranitherapeutics.com/